To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´ s disease
KR Herrlinger, EF Stange - Expert Review of Gastroenterology & …, 2023 - Taylor & Francis
Introduction The STRIDE consensus suggested to focus on mucosal healing, based on
biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This …
biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This …
[HTML][HTML] Approach to loss of response to advanced therapies in inflammatory bowel disease
N Vootukuru, A Vasudevan - World Journal of Gastroenterology, 2024 - ncbi.nlm.nih.gov
BACKGROUND Remarkable progress over the last decade has equipped clinicians with
many options in the treatment of inflammatory bowel disease. Clinicians now have the …
many options in the treatment of inflammatory bowel disease. Clinicians now have the …
Therapeutic Benefits of Tuna Oil by In Vitro and In Vivo Studies Using a Rat Model of Acetic Acid-Induced Ulcerative Colitis
Ulcerative colitis (UC), an inflammation of the colon lining, represents the main form of
inflammatory bowel disease IBD. Nutritional therapy is extremely important in the …
inflammatory bowel disease IBD. Nutritional therapy is extremely important in the …
10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification–a nationwide population …
HM Koo, YK Jun, Y Choi, CM Shin… - Therapeutic …, 2023 - journals.sagepub.com
Background: Treatments for inflammatory bowel diseases (IBD) have evolved in the era of
biologics. However, the real-world data on their usage patterns and sequencing are still …
biologics. However, the real-world data on their usage patterns and sequencing are still …
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry
M Iborra, B Caballol, A Garrido… - Journal of Crohn's …, 2024 - academic.oup.com
Abstract Background and Aims Switching from the intravenous to the subcutaneous
biosimilar infliximab (SC-IFX) has been shown to safely maintain clinical remission and …
biosimilar infliximab (SC-IFX) has been shown to safely maintain clinical remission and …
[HTML][HTML] Costo per Number Needed to Treat (NNT) di upadacitinib nel trattamento dei pazienti bio-exposed con rettocolite ulcerosa attiva da moderata a grave
F Caprioli, MC Fantini, F Marando… - Global & Regional …, 2024 - ncbi.nlm.nih.gov
Background: Only limited information is available on cost efficacy of the advanced therapies
for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs …
for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs …
Lacidophilin Modulated Gut Microbiota and Ameliorated Dextran Sulfate Sodium-Induced Mouse Colitis
Y Jingting, C Xiaoying, Z Yang, Z Jingwen, L Yingmeng… - 2024 - researchsquare.com
The prevalence of inflammatory bowel disease (IBD) has been rising significantly in recent
years. It is widely accepted that gut microbes play an essential role in the development of …
years. It is widely accepted that gut microbes play an essential role in the development of …
Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis
F Caprioli, MC Fantini, F Marando… - Global and …, 2024 - journals.aboutscience.eu
Background: Only limited information is available on cost efficacy of the advanced therapies
for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs …
for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs …
Mitteilungen der Deutschen Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten
R mit einer Normalisierung - Z Gastroenterol, 2023 - thieme-connect.com
In dieser Stellungnahme erfolgt eine Bewertung des möglichen Zusatznutzens von
Risankizumab im Vergleich zur zweckmäßigen Vergleichstherapie bei erwachsenen …
Risankizumab im Vergleich zur zweckmäßigen Vergleichstherapie bei erwachsenen …
[PDF][PDF] DRUG QUANTITY MANAGEMENT POLICY–PER DAYS
P Days - 2022 - express-scripts.com
Adalimumab products are tumor necrosis factor inhibitors (TNFis) approved for the following
uses: 1• Ankylosing spondylitis, for reducing signs and symptoms in adults with active …
uses: 1• Ankylosing spondylitis, for reducing signs and symptoms in adults with active …